BMRN stock forecast
Our latest prediction for BioMarin Pharmaceutical, Inc.'s stock price was made on the April 8, 2019 when the stock price was at 92.38$.
In the short term (2weeks), BMRN's stock price should outperform the market by 0.73%. During that period the price should oscillate between -4.30% and +4.94%.
In the medium term (3months), BMRN's stock price should outperform the market by 2.00%. During that period the price should oscillate between -10.43% and +15.84%.Get email alerts
Create a solid portfolio with BMRN
About BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
At the moment the company generates 1704M USD in revenues.
On its last earning announcement, the company reported a loss of -0.13$ per share.
The book value per share is 16.25$
Three months stock forecastApril 8, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|